Cellectis SA

Cellectis SA operates as a clinical stage biotechnological company. The firm operates through the segments: Therapeutics and Plants. The Therapeutics segment focuses on the development of products in the field of immuno-oncology and monogenic diseases. The Plants segment focuses on using Calyxt's proprietary PlantSpringTM technology platform to engineer plant metabolism to produce innovative, high-value, and sustainable materials and products for use in helping customers meet their sustainability targets and financial goals. The company was founded by David J. Sourdive and André Choulika on February 20, 1999 and is headquartered in Paris, France.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Cellectis SA operates as a clinical stage biotechnological company, which engages in gene-editing platform to develop cell and gene therapies. The company was founded by David J. Sourdive and André Choulika on February 20, 1999 and is headquartered in Paris, France.

NEW YORK, April 26, 2021 (GLOBE NEWSWIRE) -- Cellectis (Euronext Growth: ALCLS; Nasdaq: CLLS).

Cellectis' Annual Shareholders' General Meeting to be Held on June 1, 2021

(Article 223-16 of General Regulation of the French financial markets authority)

Monthly information on share capital and company voting rights

NEW YORK, April 09, 2021 (GLOBE NEWSWIRE) -- Cellectis S.A. (NASDAQ: CLLS – EURONEXT GROWTH: ALCLS) (the “Company”), a clinical-stage biotechnological company employing its core proprietary technologies to develop best-in-class products based on gene-edited allogeneic CAR T-cells in the field of immuno-oncology, today announced that it has completed sales of approximately $47 million of American Depositary Shares (“ADS”) pursuant to the Company's ATM program established on March 29, 2021 (the “ATM Sales”), through Jefferies LLC (“Jefferies”), acting as sales agent. Each ADS represents one ordinary share of the Company.

Cellectis Completes Sale of $47 million through its ATM program

Beam Therapeutics

CRISPR Therapeutics

Editas Medicine

Intellia Therapeutics

The biotech space is on the verge of hypergrowth, thanks to a scientific breakthrough in genetic editing. This is your ultimate guide to understanding and profiting from CRISPR stocks.

Investing in CRISPR Stocks: Ultimate Genetic Editing Guide

Cellectis S.A. (CLLS) CEO André Choulika on Q4 2020 Results - Earnings Call Transcript

Shares of Cellectis (NASDAQ:CLLS) were flatin after-market trading after the company reported Q4 results. Quarterly Results Earnings per share fell 20.55% year over year to ($0.88), which missed the estimate of ($0.78).

Cellectis: Q4 Earnings Insights

NEW YORK, March 04, 2021 (GLOBE NEWSWIRE) -- Cellectis (Euronext Growth: ALCLS; Nasdaq: CLLS), a clinical-stage biopharmaceutical company focused on developing immunotherapies based on allogeneic gene-edited CAR T-cells (UCART), today announced its results for the fourth quarter of 2020, and full year ending December 31, 2020.

Cellectis Provides Business Update and Reports 4th Quarter and Full Year 2020 Financial Results

NEW YORK, Feb. 25, 2021 (GLOBE NEWSWIRE) -- Cellectis (Euronext Growth: ALCLS; Nasdaq: CLLS), a clinical-stage biopharmaceutical company focused on developing immunotherapies based on gene-edited allogeneic CAR T-cells (UCART), announced that it will report its financial results for the fourth quarter and full year ending December 31, 2020, on Thursday, March 4, 2021, after the close of the US market. The announcement will be followed by a conference call at 8:00 AM EST / 2:00 PM CET on Friday, March 5, 2021, prior to the open of the US market.

Cellectis to Hold Fourth Quarter 2020 Earnings Call on Friday, March 5, 2021 at 8:00AM EST

Cytovia Therapeutics Inc and Cellectis SA (NASDAQ: CLLS) have entered into a strategic research and development collaboration to develop TALEN gene-edited induced pluripotent stem cells (iPSC) Natural Killer (NK) and Chimeric Antigen Receptor (CAR)-NK cells. Cellectis will receive up to $760 million in milestone payments from Cytovia for the first five TALEN gene-edited iPSC-derived NK products.

Cellectis, Cytovia Therapeutics Ink Gene-Edited Therapy Pact For Oncology Indications

CAMBRIDGE, Mass. and NEW YORK, Feb. 16, 2021 (GLOBE NEWSWIRE) -- Cytovia Therapeutics, Inc., a biopharmaceutical company developing allogeneic “off-the-shelf” gene-edited Natural Killer (NK) and Chimeric Antigen Receptor (CAR)-NK cells derived from induced pluripotent stem cells (iPSCs), and Cellectis (Euronext Growth: ALCLS - Nasdaq: CLLS) a clinical-stage biopharmaceutical company focused on developing immunotherapies based on gene-edited allogeneic CAR T-cells (UCART), announced today that they have entered into a strategic research and development collaboration to develop TALEN® gene-edited iPSC NK and CAR-NK cells.

Cytovia Therapeutics and Cellectis Partner to Develop TALEN® Gene-Edited iPSC-Derived Natural Killer Cells

Cellectis: Monthly information on share capital and company voting rights

Calyxt

Sangamo Therapeutics

Between these seven genetic editing pioneers, you have the widest exposure to the biggest scientific breakthrough of the century. The post 7 CRISPR Stocks for the Future of Medicine appeared first on InvestorPlace.

7 CRISPR Stocks for the Future of Medicine

Cellectis (CLLS) saw a big move last session, as its shares jumped 9% on the day, amid huge volumes.

Cellectis (CLLS) Jumps: Stock Rises 9%

NEW YORK, Dec. 15, 2020 (GLOBE NEWSWIRE) -- Cellectis (Euronext Growth: ALCLS - Nasdaq: CLLS), a clinical-stage biopharmaceutical company focused on developing immunotherapies based on gene-edited allogeneic CAR T-cells (UCART), today announced that it has withdrawn the proposed underwritten offering of American Depositary Shares (“ADS”) due to market conditions.

Cellectis Announces Withdrawal of Follow-On Offering

NEW YORK, Dec. 05, 2020 (GLOBE NEWSWIRE) -- Cellectis (Euronext Growth: ALCLS - Nasdaq: CLLS), a clinical-stage biopharmaceutical company focused on developing immunotherapies based on gene-edited allogeneic CAR T-cells (UCART), announced preliminary results from Cellectis' dose escalation Phase 1 BALLI-01 study of UCART22 product candidate in relapsed/refractory B-cell Acute Lymphoblastic Leukemia (B-ALL) were presented at the American Society of Hematology (ASH) Annual Meeting. This is the first publicly released data from Cellectis' BALLI-01 clinical trial.

Cellectis Reports Preliminary Results from its Phase 1 BALLI-01 Study of UCART22 in R/R Adult B-ALL at American Society of Hematology (ASH) Annual Meeting

Allogene Therapeutics Inc

Atara Biotherapeutics

Bristol-Myers

Gilead Sciences

Novartis

Pfizer

Allogeneic cell therapies have a significant cost, convenience and efficiency advantage over autologous. Data from three of the leaders: Allogene, Atara and CRISPR are expected in the next 12-to-24 months to further elucidate safety and efficacy.

Regenerative Medicines: Universal Cell Therapy Gaining Momentum

NEW YORK, Nov. 17, 2020 (GLOBE NEWSWIRE) -- Cellectis (Euronext Growth: ALCLS - Nasdaq: CLLS), a biopharmaceutical company focused on developing immunotherapies based on gene-edited allogeneic CAR T-cells (UCART), today announced that the U.S. Food and Drug Administration (FDA) has lifted the clinical hold on the Phase 1 MELANI-01 trial evaluating the UCARTCS1 product candidate for the treatment of patients with relapsed or refractory multiple myeloma (MM).

FDA Lifts Clinical Hold on MELANI-01 Study Evaluating Cellectis' Product Candidate UCARTCS1 in Multiple Myeloma

NEW YORK, Nov. 16, 2020 (GLOBE NEWSWIRE) -- Cellectis (Euronext Growth: ALCLS - Nasdaq: CLLS), a clinical-stage biopharmaceutical company focused on developing immunotherapies based on gene-edited allogeneic CAR T-cells (UCART), announced today the appointment of Kyung Nam-Wortman as Cellectis' Executive Vice President, Chief Human Resources Officer. Ms. Nam-Wortman, who will be based in Cellectis' New York office, is also joining the Company's executive committee.

Cellectis Appoints Pharma HR Leader Kyung Nam-Wortman as Executive Vice President, Chief Human Resources Officer

Cellectis' (CLLS) CEO André Choulika on Q3 2020 Results - Earnings Call Transcript

NEW YORK, Nov. 05, 2020 (GLOBE NEWSWIRE) -- Cellectis (Euronext Growth: ALCLS – Nasdaq: CLLS), a clinical-stage biopharmaceutical company focused on developing immunotherapies based on allogeneic gene-edited CAR T-cells (UCART), today announced its results for the three-month and nine-month periods ending September 30, 2020.

Cellectis Provides Business Update and Reports Financial Results for Third Quarter and First Nine Months 2020

NEW YORK, Nov. 04, 2020 (GLOBE NEWSWIRE) -- Cellectis (Euronext Growth: ALCLS - Nasdaq: CLLS), a clinical-stage biopharmaceutical company focused on developing immunotherapies based on gene-edited allogeneic CAR T-cells (UCART), announced the release of two abstracts at the American Society of Hematology (ASH) Annual Meeting, one oral presentation of initial data for its BALLI-01 clinical trial and one Trials in Progress poster presentation of its AMELI-01 clinical trial. This will be the first publicly released data from Cellectis' Phase 1 dose-escalation study of UCART22 product candidate in adult patients with Relapsed/Refractory CD22+ B-ALL.

American Society of Hematology (ASH) Abstract Shows Initial Anti-Leukemic Activity of UCART22 in BALLI-01 Phase 1 Study in R/R Adult B-ALL

NEW YORK, Oct. 21, 2020 (GLOBE NEWSWIRE) -- Cellectis (Euronext Growth: ALCLS; Nasdaq: CLLS), a clinical-stage biopharmaceutical company focused on developing immunotherapies based on gene-edited allogeneic CAR T-cells (UCART), announced that it will report its financial results for the third quarter of 2020 together with a business update on Thursday, November 5, 2020, after the close of the US market. The announcement will be followed by a conference call at 8:00 AM EST / 2:00 PM CET on Friday, November 6, 2020, prior to the open of the US market.

Cellectis to Hold Third Quarter 2020 Earnings Call on Friday, November 6, 2020 at 8:00AM EST

Emergent BioSolutions

Thermo Fisher Scientific

Vertex Pharmaceuticals

Advancements in gene editing have boosted the biotech space, putting the spotlight on five stocks that can make the most.

Booming Gene Editing Market to Pep Up These 5 Biotech Stocks

NEW YORK, Sept.  02, 2020  (GLOBE NEWSWIRE) --  Cellectis  (Euronext Growth: ALCLS - Nasdaq: CLLS), a clinical-stage biopharmaceutical company focused on developing immunotherapies based on gene-edited allogeneic CAR T-cells (UCART), will present at several upcoming investor conferences. Webcast information when available will be posted in the Investor Relations section of the Company’s website at  https://www.cellectis.com/en/investors/events-and-webcasts/

Cellectis to Participate in Upcoming Investor Conferences

Cellectis S.A. (CLLS) CEO André Choulika on Q2 2020 Results - Earnings Call Transcript

News for Cellectis SA Stock (CLLS)